The Production and Characterisation of a Panel of Ten Murine Monoclonal Antibodies to Human Procoagulant Factor VIII

B D Griffin; L R Micklem; M C McCann; K James; D S Pepper

doi:10.1055/s-0038-1661443

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1986; 55(01): 040-046
DOI: 10.1055/s-0038-1661443

Original Article

Schattauer GmbH Stuttgart

The Production and Characterisation of a Panel of Ten Murine Monoclonal Antibodies to Human Procoagulant Factor VIII

B D Griffin

¹The Scottish National Blood Transfusion Service Headquarters Unit Laboratory, Edinburgh, Scotland, UK

,

L R Micklem

²The Department of Surgery, University of Edinburgh Medical School, Edinburgh, Scotland, UK

,

M C McCann

²The Department of Surgery, University of Edinburgh Medical School, Edinburgh, Scotland, UK

,

K James

²The Department of Surgery, University of Edinburgh Medical School, Edinburgh, Scotland, UK

,

D S Pepper

¹The Scottish National Blood Transfusion Service Headquarters Unit Laboratory, Edinburgh, Scotland, UK

› Institutsangaben

Abstract

als PDF herunterladen

Summary

A panel of 10 murine monoclonal antibodies to procoagulant FVIII has been developed from the fusion of a single spleen. Balb/c mice were injected with a purified preparation of FVIII: Ag, and antibody production in sera and hybrid culture supernatants was monitored using a specific radiometric screening assay. The antibodies all inhibit FVIII clotting activity in normal plasma, and when immobilised on agarose retain their ability to recognise and bind the FVIII procoagulant protein. Studies on protein A-purified immunoglobulins demonstrate a range of properties within the panel of antibodies with regard to species crossreactivity, clotting inhibition and immunoadsorption. The panel of antibodies has been used to screen heat-treated FVIII concentrates for the occurrence of heat-induced neoantigens.

Key words

Factor VIII - Monoclonal antibodies

PDF (1363 kb)

Referenzen

References
1 Hoyer LW. The factor VIII complex: structure and function. Blood 1981; 58: 1-13
2 Shapiro SS, Hultin MB. Acquired inhibitors to the blood coagulation factors. Sem Thromb Haemostas 1975; 1-336
3 Fay PJ, Chavin SI, Schroeder D, Young FE, Marder VJ. Purification and characterisation of a highly purified human factor VIII consisting of a single type of polypeptide chain. Proc Nat Acad Sci USA 1982; 79: 7200-720
4 Tran TH, Marbet GA, Duckert F. Rabbit antibodies against the procoagulant activity (VIII :C) of human factor VIII. Thromb Haemostas 1981; 46: 699-705
5 Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-497
6 Sola B, Anver P, Sultan Y, Jeanneau C, Maisonneuve P. Monoclonal antibodies against the human factor VIII molecule neutralise antihemophilic factor and ristocetin cofactor activities. Proc Nat Acad Sci USA 1982; 79: 183-187
7 Brown JE, Thuy LP, Carton CL, Hougie C. Studies on a monoclonal antibody to human factor VIII coagulant activity, with a description of a facile two-site factor VIII coagulant antigen assay. J Lab Clin Med 1983; 101: 793-805
8 Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45-52
9 Rotblat F, Tuddenham EG D. Immunologic studies of factor VIII coagulant activity (VIII :C). I. Assays based on a haemophilic and an acquired antibody to VIII :C. Thromb Res 1981; 21: 431-545
10 Tuddenham EG D, Lane RS, Rotblat F, Johnson AJ, Snape TJ, Middleton S, Kernoff PB A. Response to infusions of poly electrolyte-fractionated human factor VIII concentrate in human haemophilia A and von Willebrand’s disease. Br J Haematol 1982; 52: 259-267
11 Stel HV, Veerman EC I, Huisman JG, Janssen MC, van Mourik JA. A rapid one-step immunoradiometric assay for factor VIII procoagulant antigen utilising monoclonal antibodies. Thromb Haemostas 1983; 50: 860-86
12 Mason EC, Pepper DS, Griffin B. Production of cryoprecipitate of intermediate purity in a closed system thaw-siphon process. Thromb Haemostas 1981; 46: 543-546
13 Wright JF, Hunter WM. A convenient replacement for cyanogen bromide-activated solid phases in immunoradiometric assays. J Immunol Method 1982; 48: 311-32
14 Salacinski PR R, McLean C, Sykes JE C, Clement-Jones VV, Lowry PJ. Iodination of proteins, glycoproteins and peptides using a solid phase oxidising agent, 1,3,4,6-tetrachloro 3α, 6α-diphenylglycouril (Iodogen). Anal Biochem 1981; 117: 136-146
15 Greenwood FC, Hunter WM, Glover JS. The preparation of ¹³¹I-labelled human growth hormone of high specific radioactivity. Biochem J 1963; 89: 114-123
16 Fass DN, Knutson GJ, Katzmann JA. Monoclonal antibodies to porcine factor VIII coagulant and their use in the isolation of active coagulant protein. Blood 1982; 59: 594-600
17 Hunter WM. Simplified solid phase radioimmunoassay without centrifugation. Acta Endocrinol 1977; 85 (212) 463
18 Kasper CK, Aldedort LM, Counts RB, Edson JR, Fratantoni J, Green D, Hampton JW, Hilgartner MW, Lazerson J, Levine PH, McMillan CW, Pool JG, Shapiro SS, Sulman NR, Van Eys J. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 869
19 Kohler G, Howe SC, Milstein C. Fusion between immunoglobulin-secreting and non secreting myeloma cell lines. Eur J Immunol 1976; 6: 292-295
20 Kennett RH, Denis KA, Tung AS, Klinman NR. Hybrid plasmacytoma production: fusions with adult spleen cells, monoclonal spleen fragments, neonatal spleen cells and human spleen cells. Curr Topics Microbiol Immunol 1978; 81: 77-91
21 Oi V, Herzenberg LA. Immunoglobulin producing hybrid cell lines. In: Selected Methods in Cellular Immunology Mishell BB, Shiigi SM. (eds) W H Freeman & Co; San Francisco: 1980: 351-372
22 Ey PL, Prowse SJ, Jenkins CR. Isolation of pure IgG₁, IgG_2a and IgG_2b immunoglobulins from mouse serum using protein A Sephar-ose. Immunochem 1978; 15: 429-436
23 Kohn J, Wilchek M. A new approach (cyano-transfer) for cyanogen bromide activation of Sepharose at neutral pH, which yields activated resins, free of interfering nitrogen derivatives. Biochem Biophys Res Commun 1982; 107: 878-884
24 Tuddenham EG D, Trabold NC, Hoyer LW. The properties of factor VIII coagulant activity prepared by immunoadsorbent chromatography. J Lab Clin Med 1979; 93: 40-53
25 Rotblat F, Hawkey C, O’Brien DP, Tuddenham EG D. Immunologic studies of factor VIII coagulant activity (VIII :C). 2. Factor VIII in selected vertebrates. Thromb Res 1982; 25: 423-431
26 Bier M, Foster PR. Purification of antihemophilia factor VIII by precipitation with zinc ions. U S Patent 4, 406, 886. Sept 27 1983
27 Rotblat F, Goodall AH, O’Brien DP, Rawlings E, Middleton S, Tuddenham EG D. Monoclonal antibodies to human procoagulant factor VIII. J Lab Clin Med 1983; 101: 736-746
28 Muller HP, van Tilburg NH, Derks J, Klein-Breteler E, Bertina RM. A monoclonal antibody to VIII: C produced by a mouse hybridoma. Blood 1981; 58: 1000-1006
29 Gawryl MS, Hoyer LW. Inactivation of FVIII coagulant activity by two different types of human antibodies. Blood 1982; 60: 1103-1109
30 Vehar GA, Keyt B, Eaton D, Rodriguez H, O’Brien DP, Rotblat F, Oppermann H, Keck R, Wood WI, Harkins RN, Tuddenham EG D, Lawn RM, Capon DJ. Structure of human factor VIII. Nature 1984; 312: 337-342
31 Moake JL, Weinstein MJ, Troll JH, Chute LE, Colannino NM. Direct radioimmune detection in human plasma of the association between factor VIII procoagulant protein and von Willebrand factor, and the interaction of von Willebrand factor-bound procoagulant VIII with platelets. Blood 1983; 61: 1167-1173
32 Joshua DE, Exner T, Holmes D, Rickard KA, Kronenberg H. Antibodies to human factor VIII complex from Balb/c mice. Thromb Res 1981; 22: 345-352
33 Bird AG, Codd AA, Collins A. Haemophilia and AIDS. Lancet 1985; 1: 162-163